TempraMed Technologies Ltd., a medical-technology company focused on improving the storage and handling of temperature-sensitive medications, has secured a new commercial order and extended its distribution partnership in South Korea, strengthening its presence in the Asian healthcare market.

The expanded collaboration with Mavericks Co. Ltd. (Mavens), a South Korea-based healthcare distribution company, follows the recent grant of a South Korean patent protecting TempraMed’s proprietary thermal insulation technology. Leveraging Mavens’ established relationships across the country’s healthcare ecosystem, the partnership is expected to enhance TempraMed’s reach to pharmacies, hospitals, clinics, and patient communities nationwide.

South Korea represents one of Asia’s fastest-growing markets for injectable therapies, underpinned by a strong pharmaceutical manufacturing base and rising healthcare demand. The country’s pharmaceutical market is among the largest in the region and is projected to expand steadily over the coming decade.

Within this landscape, diabetes treatments—including insulin and newer non-insulin injectable therapies—continue to see robust growth. The South Korean diabetes drugs market alone is valued at close to USD 1 billion, driven by an aging population and changing lifestyle patterns.

As the use of temperature-sensitive therapies such as insulin, GLP-1 receptor agonists, biologics, and emergency injectables increases, ensuring medication stability during daily use has become a critical challenge. Exposure to heat or cold can compromise drug potency, underscoring the need for reliable, passive thermal protection solutions.

The extended distribution agreement deepens TempraMed’s integration into South Korea’s healthcare and retail channels and is expected to accelerate market penetration. The move builds on the company’s recent distribution expansions across Turkey, Israel, and several European markets, highlighting its broader global growth strategy.

“Our collaboration with TempraMed has clearly demonstrated the value of practical, patient-focused solutions for injectable medications,” said Chang Gyu An, CEO of Mavens. “This expanded agreement allows us to build on existing momentum and further embed these solutions within South Korea’s healthcare and pharmacy network.”

Ron Nagar, CEO of TempraMed, said the timing of the expansion aligns with rising demand for injectable therapies in the country. “With our newly granted patent, a strengthened local partnership, and the recent launch of our VIVI Cap Smart device, we are well positioned to support the South Korean healthcare market. This partnership enables us to deliver reliable temperature-protection solutions that help safeguard medication quality and improve patient outcomes.”

TempraMed Technologies develops patented, FDA-registered thermal insulation devices designed to protect temperature-sensitive medications without the use of batteries or external power. Its product portfolio includes VIVI Cap and VIVI Epi, with additional smart technology solutions under development to support patients and healthcare providers worldwide.